DeepScribe

Specialty-focused ambient scribe with built-in coding, enterprise-only

Productivity Enterprise
Researched · Published · Reviewed
RECATOOLS Score
7.2 / 10
Capability
7.5
Value for money
6.5
Ease of use
7.5
ASEAN readiness
3.5
API quality
Founded
HQ
Users
Launched
Developer

Overview

DeepScribe is an ambient AI scribe that documents consultations and automates E/M, ICD-10, and HCC coding, with particular depth in oncology and specialty care. It integrates with Epic, Athenahealth, and eClinicalWorks, and sells exclusively through enterprise contracts.

Advertisement

What you can produce with DeepScribe

  • Ambient consultation-to-note transcription
  • Automated E/M, ICD-10, and HCC coding suggestions
  • SmartPrep pre-visit context summaries
  • Specialty and oncology-specific templates
  • Epic, athenahealth, eClinicalWorks integration
  • Clinician-specific customization studio
Advertisement

ASEAN Perspective

DeepScribe in Southeast Asia

ASEAN-region availability and pricing notes coming soon. Drop the editorial team a note via /contact/ if you can supply local context (Singapore/Malaysia/Indonesia/Thailand/Vietnam).

RECATOOLS Verdict

DeepScribe's pitch goes past note-taking into revenue cycle: automated E/M, ICD-10, and HCC coding alongside the transcript, plus a pre-visit context tool (SmartPrep) and deep specialty/oncology templates that generalist scribes don't bother building. KLAS scored it 98.8 out of 100 in 2025, and Capterra reviewers rate it 4.3/5 across a small sample, with ease of use and customer service the strongest categories.

The catch is access: DeepScribe doesn't publish pricing, requires an enterprise sales process, and street estimates put real-world cost at $200-750+/month per provider depending on volume and integration depth — well above most solo-clinician scribes. It's US-market and Epic/athenahealth-centric, with $24 million in disclosed Series B funding, so it's built for hospital systems and specialty groups with budget and IT support, not a solo GP shopping on price.

Independent AI-assisted assessment by RECATOOLS.

What people say

DeepScribe listens to the visit and produces the note, but its differentiator is what happens after: automated E/M level, ICD-10, and HCC coding suggestions layered onto the transcript, aimed at practices that live or die on coding accuracy for reimbursement. SmartPrep pulls prior-visit context before the appointment starts, and a customization studio lets it adapt to an individual clinician's phrasing over repeated use. Specialty depth — oncology in particular — is where DeepScribe differentiates from broader ambient scribes.

KLAS Research scored DeepScribe 98.8 out of 100 in its 2025 evaluation, a genuinely strong result in a category KLAS tracks closely for enterprise health-system buyers. Capterra shows a smaller sample — 4.3 out of 5 across 8 verified reviews — with ease of use at 4.5, customer service at 4.6, features at 4.0, and value for money at 4.4; an aggregate satisfaction figure elsewhere put it at 83% across 34 reviews on two review sites. The features score being the relative laggard tracks with what specialty users report: broad and strong for common workflows, occasionally missing edge-case templates for less common specialties.

DeepScribe doesn't publish pricing anywhere and requires practices to go through enterprise sales before seeing a number. Third-party estimates put real cost between $200 and $750+ a month per provider depending on visit volume, EHR integration depth, and customization, with $350-500/month cited as a typical range — expensive enough that reviewers specifically flag cost as a barrier for smaller practices and solo providers even when they rate the product itself well.

The company has raised $24 million in Series B funding and serves more than 1,500 healthcare organizations, with integrations into Epic, athenahealth, and eClinicalWorks — the EHRs that matter for US enterprise and specialty groups. There's no indication of international expansion or ASEAN presence; this is a US enterprise sale end to end, and no acquisition news surfaced despite periodic speculation in the space.

Summary of public user & expert reviews, compiled by RECATOOLS.

About this listing

Researched on
Published on
Last reviewed

This entry was compiled from publicly available data including DeepScribe's official website, press releases, documentation, and reputable third-party publications. RECATOOLS is not affiliated with DeepScribe unless explicitly stated.

Data accuracy

Third-party AI tools update their pricing, features, availability, and policies frequently. Information here may be outdated by the time you read this — we make reasonable efforts to keep listings current, but cannot guarantee absolute accuracy.

For the latest details, please refer to DeepScribe directly →

Spotted something out of date? Suggest an update →

Advertisement